I. Background

This guidance, when finalized, is intended to assist drug sponsors and device manufacturers who are planning to develop new antimicrobial drugs and AST devices and who seek to coordinate development of these products such that the AST device could be cleared either at the time of new drug approval or shortly thereafter.

Specifically, the guidance intends to describe the interactions between drug sponsors and device manufacturers for coordinated development of a new antimicrobial drug and an AST device; explain the considerations for submitting separate applications to the Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH) when seeking clearance of an AST device coincident with, or soon following, antimicrobial drug approval; and clarify that the review of the new antimicrobial drug product and AST device(s) will remain independent, and that coordinated development does not influence the review timelines for either product.

II. Significance of Guidance

This draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on coordinated development of antimicrobial drugs and antimicrobial susceptibility test devices. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

III. Electronic Access

Persons interested in obtaining a copy of the draft guidance may do so by downloading an electronic copy from the Internet. A search capability for all Center for Devices and Radiological Health guidance documents is available at http://www.fda.gov/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/default.htm, and a search capability for all Center for Drug Evaluation and Research guidance documents is available at http://www.fda.gov/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/default.htm. Guidance documents are also available at http://www.regulations.gov. Persons unable to download an electronic copy of “Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices” may send an email request to CDRH-Guidance@fda.hhs.gov to receive an electronic copy of the document. Please use the document number 1400061 to identify the guidance you are requesting.

IV. Paperwork Reduction Act of 1995

This draft guidance refers to previously approved collections of information. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520). The collections of information in 21 CFR part 807, subpart E have been approved under OMB control number 0910–0120, the collections of information in 21 CFR part 812 have been approved under OMB control number 0910–0078, the collections of information in 21 CFR part 314 have been approved under OMB control number 0910–0014, and the collections of information in 21 CFR part 314 have been approved under OMB control number 0910–0001. The collections of information in the guidance document “Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff” have been approved under OMB control number 0910–0756.

Dated: September 15, 2016.

Leslie Kux,
Associate Commissioner for Policy.

[FR Doc. 2016–23111 Filed 9–20–16; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2011–P–0081]

Armenpharm, Ltd.; Suspension of Approval of an Abbreviated New Drug Application for Chloramphenicol Capsules, 250 Milligrams; Determination That CHLOROMYCETIN (Chloramphenicol) Capsules, 50 Milligrams and 100 Milligrams, and Three Other Products Were Withdrawn From Sale for Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is suspending approval of abbreviated new drug application (ANDA) 060851 for chloramphenicol capsules, 250 milligrams (mg), held by Armenpharm, Ltd. (Armenpharm), 49 South Ridge Rd., P.O. Box D1400, Pomona, NY 10970. FDA has also determined that CHLOROMYCETIN (chloramphenicol) Capsules, 50 mg and 100 mg; AMPHICOL (chloramphenicol) Capsules, 100 mg; and CHLOROMYCETIN PALMITATE (chloramphenicol palmitate) Oral Suspension, 150 mg/5 milliliters (mL) were withdrawn from sale for reasons of safety or effectiveness. The Agency will not accept or approve ANDAs for...
Under § 314.161(a) (21 CFR 314.161(a)), the Agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness: (1) Before an ANDA that refers to that listed drug may be approved, (2) whenever a listed drug is voluntarily withdrawn from sale and ANDAs that refer to the listed drug have been approved, and (3) when a person petitions for such a determination under 21 CFR 10.25(a) and 10.30. FDA may not approve an ANDA that does not refer to a listed drug.

Section 505(j)(6) of the FD&C Act authorizes FDA to suspend approval of an ANDA if the listed drug relied upon has been withdrawn from sale for what FDA determines are safety or effectiveness reasons. Section 314.161(d) provides that if FDA determines that a listed drug was withdrawn from sale for safety or effectiveness reasons, the Agency will initiate proceedings under § 314.153(b) (21 CFR 314.153(b)) that could result in the suspension of approval of the ANDAs that refer to the listed drug.

II. Chloramphenicol Capsules, 250 mg

On February 7, 2011, Armenpharm submitted a citizen petition under § 10.30 (Docket No. FDA–2011–P–0081), requesting that the Agency determine whether CHLOROMYCETIN (chloramphenicol) Capsules, 250 mg (ANDA 060591), was withdrawn from sale for reasons of safety or effectiveness. CHLOROMYCETIN (chloramphenicol) Capsules, 250 mg, is the listed drug that was the basis of submission for Armenpharm’s ANDA 060851 for chloramphenicol capsules, 250 mg. In the Federal Register of July 13, 2012 (77 FR 41412), FDA published a notice stating its determination under § 314.161 that CHLOROMYCETIN (chloramphenicol) Capsules, 250 mg, was withdrawn from sale for reasons of safety or effectiveness. FDA also notified Armenpharm of the Agency’s decision in a letter dated July 13, 2012.

Pursuant to § 314.153(b)(1), FDA initiated the process to suspend Armenpharm’s chloramphenicol ANDA 060851 by sending a letter, dated December 3, 2015, notifying Armenpharm of the Agency’s initial determination that CHLOROMYCETIN (chloramphenicol) Capsules, 250 mg, was withdrawn for reasons of safety or effectiveness and its initial decision to suspend approval of ANDA 060851 (see Docket No. FDA–2011–P–0081). Under § 314.153(b)(2), Armenpharm had 30 days from that notification in which to present written comments or information bearing on the initial decision. On December 17, 2015, Armenpharm submitted comments requesting an oral hearing under § 314.153(b)(4). However, on March 17, 2016, Armenpharm withdrew its oral hearing request.

Therefore, under section 505(j)(6) of the FD&C Act and § 314.153(b), and under authority delegated by the Commissioner to the Director, Center for Drug Evaluation and Research, approval of ANDA 060851, and all amendments and supplements thereto, is suspended (see DATES). FDA has removed all chloramphenicol capsules, 250 mg, from the list of drug products published in the Orange Book, and no chloramphenicol capsules, 250 mg, will be listed in the Orange Book. Distribution of chloramphenicol capsules, 250 mg, in interstate commerce without an approved application is illegal and subject to regulatory action (see sections 505(a) and 301(d) of the FD&C Act (21 U.S.C. 355(a) and 331(d)).

III. Other Discontinued Oral Chloramphenicol Drug Products

FDA has become aware that the oral chloramphenicol drug products listed in the table in this document are no longer being marketed.

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug</th>
<th>Applicant</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA 060591 .......</td>
<td>CHLOROMYCETIN (chloramphenicol) Capsules, 50 mg and 100 mg</td>
<td>Parkedale Pharmaceuticals Inc. (formerly Parke Davis Pharmaceutical Research Division of Warner Lambert Co.)</td>
</tr>
<tr>
<td>ANDA 062301 .......</td>
<td>CHLOROMYCETIN PALMITATE (chloramphenicol palmitate) Oral Suspension, Equivalent to (EQ) 150 mg base/5 mL</td>
<td>Parkedale Pharmaceuticals Inc. (formerly Parke Davis Pharmaceutical Research Division of Warner Lambert Co.)</td>
</tr>
<tr>
<td>ANDA 060058 .......</td>
<td>AMPHICOL (chloramphenicol) Capsules, 100 mg ...</td>
<td>John J. Ferrante.</td>
</tr>
<tr>
<td>NDA 050152 .......</td>
<td>CHLOROMYCETIN PALMITATE (chloramphenicol palmitate) Oral Suspension, EQ 150 mg base/5 mL</td>
<td>Parkedale Pharmaceuticals Inc. (formerly Parke Davis Pharmaceutical Research Division of Warner Lambert Co.).</td>
</tr>
</tbody>
</table>

FDA has reviewed its records and, under § 314.161, has determined that the drug products listed in this table were withdrawn from sale for reasons of safety or effectiveness. We have carefully reviewed Agency records concerning the withdrawal from sale of the drug products listed in the table. We have also independently evaluated relevant literature and data for possible postmarketing adverse events. At the time of the approval of the drug
products listed in the table, there was significant unmet medical need. With
the approval of additional therapies with less severe adverse drug effects,
FDA has determined that the risks associated with CHLOROMYCETIN
(chloramphenicol) Capsules, 50 mg and 100 mg; AMPHICOL (chloramphenicol)
Capsules, 100 mg; and
CHLOROMYCETIN PALMITATE
(chloramphenicol palmitate) Oral Suspension, 150 mg/5 mL, as currently
labeled, outweigh the benefits. Most important, CHLOROMYCETIN
(chloramphenicol) Capsules, 50 mg and 100 mg; AMPHICOL (chloramphenicol)
Capsules, 100 mg; and
CHLOROMYCETIN PALMITATE
(chloramphenicol palmitate) Oral Suspension, 150 mg/5 mL, may cause a
number of adverse reactions, the most serious being bone marrow depression
(anemia, thrombocytopenia, and granulocytopenia temporarily associated
with treatment). A boxed warning in the prescribing information for
chloramphenicol sodium succinate injection and chloramphenicol capsules
and oral suspension states that serious hypoplastic anemia, thrombocytopenia,
and granulocytopenia are known to occur after administration of
chloramphenicol. The drug product labeling recommends extensive safety
monitoring, including baseline blood studies followed by periodic blood
studies approximately every 2 days during therapy. The boxed warning also
describes fatal aplastic anemia associated with administration of the
drug and aplastic anemia attributed to chloramphenicol that later terminated
in leukemia. Published literature suggests that the risk of fatal aplastic
anemia associated with oral formulations of chloramphenicol may be higher than the risk associated with the intravenous formulation.

FDA has also reviewed approved labeling for the products and has
determined that a Risk Evaluation and Mitigation Strategy (REMS) would be
required to ensure that the benefits of the drug outweigh its risks. The REMS
may include Elements to Assure Safe Use, including restricted distribution,
and a Medication Guide could be required as part of the labeling. FDA has
determined that additional nonclinical and possibly clinical studies of safety
and efficacy would be necessary before CHLOROMYCETIN (chloramphenicol)
Capsules, 50 mg and 100 mg; AMPHICOL (chloramphenicol)
Capsules, 100 mg; and
CHLOROMYCETIN PALMITATE
(chloramphenicol palmitate) Oral Suspension, 150 mg/5 mL, could be
considered for reintroduction to the market.

Accordingly, the Agency will remove
CHLOROMYCETIN (chloramphenicol) Capsules, 50 mg and 100 mg;
AMPHICOL (chloramphenicol)
Capsules, 100 mg; and
CHLOROMYCETIN PALMITATE
(chloramphenicol palmitate) Oral Suspension, 150 mg/5 mL, from the list of
drug products published in the Orange Book. FDA will not accept or
approve ANDAs that refer to these drug products.

Dated: September 14, 2016.

Leslie Kux,
Associate Commissioner for Policy.

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Food and Drug Administration


Reporting of Computational Modeling Studies in Medical Device
Submissions; Guidance for Industry and Food and Drug Administration
Staff; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
Administration (FDA or Agency) is
announcing the availability of the
guidance entitled “Reporting of
Computational Modeling Studies in
Medical Device Submissions.” The
purpose of this guidance document is to
provide recommendations to industry
on the formatting, organization, and
content of reports of computational
modeling and simulation (CM&S)
studies that are used as valid scientific
evidence to support medical device
submissions, and to assist FDA staff in
the review of computational modeling
and simulation studies by improving the
consistency and predictability of the
review of CM&S and facilitating full
interpretation and complete review of
those studies.

DATES: Submit either electronic or
written comments on this guidance at
any time. General comments on Agency
guidance documents are welcome at any
time.

ADDRESSES: You may submit comments as follows:

Electronic Submissions
Submit electronic comments in the
following way:

• Federal eRulemaking Portal: http://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to http://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number,
or confidential business information,
such as a manufacturing process. Please
note that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be

• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
“Instructions.”

Instructions: All submissions received
must include the Docket No. [FDA–
2013–D–1530] for “Reporting of
Computational Modeling Studies in
Medical Device Submissions.” Received
comments will be placed in the docket
and, except for those submitted as
“Confidential Submissions,” publicly
viewable at http://www.regulations.gov
or at the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.

Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
“This DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.” The
Agency will review this copy, including